Global human health is increasingly challenged by emerging viral threats, especially those observed over the last 20 years with coronavirus-related human diseases, such as the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS). Recently, in late December 2019, a novel Betacoronavirus , SARS-CoV-2, originating from the Chinese city of Wuhan, emerged and was then identified as the causative agent of a new severe form of pneumonia, COVID-19. Real-time genome sequencing in such viral outbreaks is a key issue to confirm identification and characterization of the involved pathogen and to help establish public health measures. Here, we implemented an amplicon-based sequencing approach combined with easily deployable next-generation sequencers, the small and hand-held MinION sequencer and the latest most compact Illumina sequencer, the iSeq100 TM system. Our results highlighted the great potential of the amplicon-based approach to obtain consensus genomes of SARS-CoV-2 from clinical samples in just a few hours. Both these mobile next-generation sequencers are proven to be efficient to obtain viral sequences and easy to implement, with a minimal laboratory environment requirement, providing useful opportunities in the field and in remote areas.
【저자키워드】 COVID-19, SARS-CoV-2, MinION, amplicon-based sequencing, real-time genome sequencing, iSeq100TM system, 【초록키워드】 Pneumonia, MERS, Laboratory, Genome sequencing, Health, pathogen, Wuhan, respiratory, Illumina, Middle East, Threats, human diseases, public health measures, help, Chinese, viral outbreak, approach, consensus genome, clinical sample, viral sequence, involved, increasingly, next-generation sequencer, 【제목키워드】 Rapid, Illumina, characterization, Direct, System,